SUPPLEMENTARY INFORMATION: You may call 202–452–3206 beginning at approximately 5 p.m. two business days before the meeting for a recorded announcement of bank and bank holding company applications scheduled for the meeting; or you may contact the Board's Web site at http://www.federalreserve.gov for an electronic announcement that not only lists applications, but also indicates procedural and other information about the meeting.

Dated: December 30, 1998.

Jennifer J. Johnson,

Secretary of the Board.

[FR Doc. 98–34825 Filed 12–30–98; 10:32 am]

BILLING CODE 6210–01–P

FEDERAL RETIREMENT THRIFT INVESTMENT BOARD

Sunshine Act Meeting

TIME AND DATE: 10:00 a.m. (EST) January 11, 1999.

PLACE: 4th Floor, Conference Room 4506, 1250 H Street, N.W., Washington, D.C.

STATUS: Open.

MATTERS TO BE CONSIDERED:

1. Approval of the minutes of the December 14, 1998, Board member meeting.
2. Thrift Savings Plan activity report by the Executive Director.

CONTACT PERSON FOR MORE INFORMATION: Thomas J. Trabucco, Director, Office of External Affairs, (202) 942–1640.

Dated: December 30, 1998.

John J. O'Meara,

Secretary to the Board, Federal Retirement Thrift Investment Board.

[FR Doc. 98–34829 Filed 12–30–98; 1:27 pm]

BILLING CODE 6760–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary

Findings of Scientific Misconduct

AGENCY: Office of the Secretary, HHS.

ACTION: Notice.

SUMMARY: Notice is hereby given that the Office of Research Integrity (ORI) has made a final finding of scientific misconduct in the following case:

Saptarshi Paul, Ph.D., Fox Chase Cancer Center: Based on a report forwarded to the Office of Research Integrity (ORI) by Fox Chase Cancer Center (FCCC), Institute for Cancer Research, dated July 28, 1997, Dr. Paul's admissions, and information obtained by ORI during its oversight review, ORI found that Dr. Paul, former research associate, Molecular Oncology Division, FCCC, engaged in scientific misconduct in biomedical research funded by a National Cancer Institute (NCI), National Institutes of Health (NIH), grant. This project seeks improvements in cancer treatment through the development of agents that fight cellular resistance to drugs.

Specifically, Dr. Paul falsified an experiment on the uptake of all-trans retinoic acid (ATR) by HL60 cells conducted by several researchers during July 1997. Although this experiment was not published, the discovery of the falsified data led to admissions by Dr. Paul that he had altered an experiment and an acknowledgment that publications would need to be retracted. Several publications were retracted in whole or in part, and portions of two grant applications were retracted.

Dr. Paul has accepted the ORI finding and has entered into a Voluntary Exclusion Agreement with ORI in which he has voluntarily agreed, for the three (3) year period beginning December 18, 1998:

(1) To exclude himself from any contracting or subcontracting with any agency of the United States Government and from eligibility for, or involvement in nonprocurement transactions (e.g., grants and cooperative agreements) of the United States Government as defined in 45 C.F.R. Part 76 (Debarment Regulations); and

(2) To exclude himself from serving in any advisory capacity to the Public Health Service (PHS), including but not limited to service on any PHS advisory committee, board, and/or peer review committee, or as a consultant.

FOR FURTHER INFORMATION CONTACT: Acting Director, Division of Research Investigations, Office of Research Integrity, 5515 Security Lane, Suite 700, Rockville, MD 20852, (301) 443–5330

Chris B. Pascal,

Acting Director, Office of Research Integrity.

[FR Doc. 98–34760 Filed 12–31–98; 8:45 am]

BILLING CODE 4160–17–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Hematology and Pathology Devices Panel of the Medical Devices Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). At least one portion of the meeting will be closed to the public.

Name of Committee: Hematology and Pathology Devices Panel of the Medical Devices Advisory Committee.

General Function of the Committee: To provide advice and recommendations to the agency on FDA's regulatory issues.

Date and Time: The meeting will be held on January 19, 1999, 9:30 a.m. to 4 p.m., and January 20, 1999, 9 a.m. to 4:30 p.m.

Location: Holiday Inn, Walker/Whetstone Salons, Two Montgomery Village Ave., Gaithersburg, MD.

Contact Person: Veronica J. Calvin, Center for Devices and Radiological Health (HFZ–440), Food and Drug Administration, 2098 Gaither Rd., Rockville, MD 20850, 301–594–1243, or FDA Advisory Committee Information Line, 1–800–741–8138 (301–443–0572 in the Washington, DC area), code 12515. Please call the Information Line for up-to-date information on this meeting.

Agenda: On January 20, 1999, the committee will: (1) Discuss, make recommendations, and vote on a petition for reclassification of automated differential cell counters in Class III and (2) establish a new classification for flow cytometers.

Procedure: On January 20, 1999, from 9 a.m. to 4:30 p.m., the meeting is open to the public. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by January 6, 1999. Oral presentations from the public will be scheduled between approximately 9:15 a.m. and 9:45 a.m. Near the end of the committee deliberations, a 30-minute open public session will be conducted for interested persons to address issues specific to the submission or topic before the committee. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before January 6, 1999, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.

Closed Committee Deliberations. On January 19, 1999, from 9:30 a.m. to 4 p.m., the meeting will be closed to the public. The committee will hear and review trade secret and/or confidential commercial information on a product